SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. & Advises Investors with Losses to ...
November 15 2016 - 3:57PM
Business Wire
Goldberg Law PC, a national shareholder rights litigation firm,
announces that it is investigating Puma Biotechnology, Inc. (“Puma”
or the “Company”) (NYSE: PBYI) concerning possible violations of
federal securities laws.
If you purchased or otherwise acquired Puma shares and would
like more information regarding the investigation, we encourage you
to contact Michael Goldberg or Brian Schall, of Goldberg Law PC,
1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights without cost to you. You can
also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The investigation focuses on whether Puma and certain of its
officers and/or directors violated federal securities laws. On
November 14, 2016, news of an investigation of an open-label Phase
2 clinical trial (“CONTROL”) was revealed. The investigation
concerned the incidence rate of severe diarrhea (grade 3) in early
stage HER2+ breast cancer patients receiving Puma’s Neratinib drug
(the “incidence rate”). Following this high incidence of
approximately 40%, the CONTROL study investigated the incidence
rate where the antidiarrheal prophylaxis Loperamide was dispensed.
The investigation showed a high incidence rate stayed at about 27%
and that the CONTROL study was then extended to include a group of
patients who were administered Loperamide and the corticosteroid
Budesonide. The incidence rate did drop, but was still at
12.9%. When this news was announced, shares of Puma fell in
value.
If you have any questions concerning your legal rights, please
immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com, or email us at
info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161115006735/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2023 to Apr 2024